FTY720 for cancer therapy (Review)

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2571-2578

  Zhang, Li ^a   Wang, Han Dong ^a   Ji, Xiang Jun ^a   Cong, Zi Xiang ^a   Zhu, Jian Hong ^a   Yuan, Zhou ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cancer; FTY720; Molecular targets

Indexed keywords

CYCLIN D1; FINGOLIMOD; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN 14 3 3; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHATIC LEUKEMIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; STOMACH CARCINOMA;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NEOPLASMS; PHOSPHORYLATION; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84892428560     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2765     Document Type: Review

References (98)

1. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N and Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278: 47408-47415, 2003.
2. Paugh SW, Payne SG, Barbour SE, Milstien S and Spiegel S: The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554: 189-193, 2003.
3. Suzuki S, Enosawa S, Kakefuda T, et al: A novel immunosup-pressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 61: 200-205, 1996.
4. Enosawa S, Suzuki S, Kakefuda T, Li XK and Amemiya H: Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology 34: 171-179, 1996.
5. Suzuki S, Li XK, Shinomiya T, et al: Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720. Transplant Proc 28: 2049-2050, 1996.
6. Suzuki S, Enosawa S, Kakefuda T, Amemiya H, Hoshino Y and Chiba K: Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720. Transplant Proc 28: 1375-1376, 1996.
7. Suzuki S, Enosawa S, Kakefuda T, et al: Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats. Transplant Immunol 4: 252-255, 1996.
8. Pitman MR, Woodcock JM, Lopez AF and Pitson SM: Molecular targets of FTY720 (fingolimod). Curr Mol Med 12: 1207-1219, 2012.
9. Azuma H, Takahara S, Ichimaru N, et al: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62: 1410-1419, 2002.
10. Sonoda Y, Yamamoto D, Sakurai S, et al: FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 281: 282-288, 2001.
11. Chua CW, Lee DT, Ling MT, et al: FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 117: 1039-1048, 2005.
12. Schmid G, Guba M, Papyan A, et al: FTY720 inhibits tumor growth and angiogenesis. Transplant Proc 37: 110-111, 2005.
13. Zhang N, Qi Y, Wadham C, et al: FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy 6: 1157-1167, 2010.
14. Lee TK, Man K, Ho JW, et al: FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 25: 2397-2405, 2004.
15. Vadas M, Xia P, McCaughan G and Gamble J: The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta 1781: 442-447, 2008.
16. Wang JD, Takahara S, Nonomura N, et al: Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40: 50-55, 1999.
17. Hu S, Vincenz C, Buller M and Dixit VM: A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 272: 9621-9624, 1997.
18. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326 (Pt 1): 1-16, 1997.
19. Zheng T, Meng X, Wang J, et al: PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem 111: 218-228, 2010.
20. Ubai T, Azuma H, Kotake Y, et al: FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res 27: 75-88, 2007.
21. Yasui H, Hideshima T, Raje N, et al: FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 65: 7478-7484, 2005.
22. Susin SA, Lorenzo HK, Zamzami N, et al: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397: 441-446, 1999.
23. Liu Q, Alinari L, Chen CS, et al: FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 16: 3182-3192, 2010.
24. Liu Q, Zhao X, Frissora F, et al : FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111: 275-284, 2008.
25. Wallington-Beddoe CT, Hewson J, Bradstock KF and Bendall LJ: FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 7: 707-715, 2011.
26. Liao A, Hu R, Zhao Q, et al: Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci 45: 600-605, 2012.
27. Alinari L, Baiocchi RA and Praetorius-Ibba M: FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? Autophagy 8: 416-417, 2012.
28. Alinari L, Mahoney E, Patton J, et al : FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood 118: 6893-6903, 2011.
29. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
30. Levine B and Yuan J: Autophagy in cell death: an innocent convict? J Clin Invest 115: 2679-2688, 2005.
31. Ogata M, Hino S, Saito A, et al: Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26: 9220-9231, 2006.
32. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P and Vandenabeele P: Autophagy: for better or for worse. Cell Res 22: 43-61, 2012.
33. Estrada-Bernal A, Palanichamy K, Ray Chaudhury A and Van Brocklyn JR: Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol 14: 405-415, 2012.
34. Ng KT, Man K, Ho JW, et al: Marked suppression of tumor growth by FTY720 in a rat liver tumor model: The significance of downregulation of cell survival Akt pathway. Int J Oncol 30: 375-380, 2007.
35. Zhou C, Ling MT, Kin-Wah Lee T, Man K, Wang X and Wong YC: FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 233: 36-47, 2006.
36. Kappos L, Radue EW, O'Connor P, et al: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401, 2010.
37. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y and Katsuoka Y: Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 169: 2372-2377, 2003.
38. Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS and Lele RD: Free radicals and antioxidants in human health: current status and future prospects. J Assoc Physicians India 52: 794-804, 2004.
39. Hung JH, Lu YS, Wang YC, et al: FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 68: 1204-1212, 2008.
40. Omar HA, Chou CC, Berman-Booty LD, et al: Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 53: 1943-1958, 2011.
41. Perrotti D and Neviani P: Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14: e229-e238, 2013.
42. Yin X, Zhang N and Di W: Regulation of LC3-dependent protective autophagy in ovarian cancer cells by protein phosphatase 2A. Int J Gynecol Cancer 23: 630-641, 2013.
43. Yang Y, Huang Q, Lu Y, Li X and Huang S: Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 113: 1314-1322, 2012.
44. Saddoughi SA, Gencer S, Peterson YK, et al: Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 5: 105-121, 2013.
45. Neviani P, Santhanam R, Trotta R, et al: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8: 355-368, 2005.
46. Neviani P, Santhanam R, Oaks JJ, et al: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117: 2408-2421, 2007.
47. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ and Odero MD: PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25: 606-614, 2011.
48. + cancers. Cancer Res 70: 5438-5447, 2010.
49. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science 298: 1912-1934, 2002.
50. Nagaoka Y, Otsuki K, Fujita T and Uesato S: Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull 31: 1177-1181, 2008.
51. Lee YJ, Kim NY, Suh YA and Lee C: Involvement of ROS in curcumin-induced autophagic cell death. Korean J Physiol Pharmacol 15: 1-7, 2011.
52. Liu JM, Pan F, Li L, et al: Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun 437: 87-93, 2013.
53. Borders EB, Bivona C and Medina PJ: Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 67: 2095-2106, 2010.
54. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412, 2008.
55. LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50, 2008.
56. Alvarez M, Roman E, Santos ES and Raez LE: New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther 7: 1423-1437, 2007.
57. Rosell R, Felip E, Garcia-Campelo R and Balana C: The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46: 135-148, 2004.
58. Zheng J, Zou X and Yao J: The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells. Chemotherapy 58: 273-281, 2012.
59. Liao WT, Li TT, Wang ZG, et al: MicroRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res 19: 4662-4672, 2013.
60. Yothaisong S, Dokduang H, Techasen A, et al: Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol: Jul 6, 2013 (Epub ahead of print).
61. Wu P and Hu YZ: PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 17: 4326-4341, 2010.
62. Ghayad SE and Cohen PA: Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 5: 29-57, 2010.
63. Cortot A, Armand JP and Soria JC: PI3K-AKT-mTOR pathway inhibitors. Bull Cancer 93: 19-26, 2006 (In French).
64. Chua CW, Chiu YT, Yuen HF, et al: Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 15: 4322-4335, 2009.
65. Li MH, Hla T and Ferrer F: FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer 60: 1418-1423, 2013.
66. Chang CY, Ma KH, Wang JK, Tung YL and Chueh SH: Inhibition of protein kinase C promotes differentiation of neuroblastoma x glioma NG108-15 hybrid cells. Eur J Neurosci 34: 1074-1084, 2011.
67. Weng JR, Bai LY, Chiu CF, Hu JL, Chiu SJ and Wu CY: Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor gamma activation. Evid Based Complement Alternat Med 2013: 935675, 2013.
68. Tolba MF, Esmat A, Al-Abd AM, et al: Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life 65: 716-729, 2013.
69. Li X, Pu J, Jiang S, et al : Henryin, an ent-kaurane diterpenoid, inhibits Wnt signaling through interference with beta-catenin/TCF4 interaction in colorectal cancer cells. PLoS One 8: e68525, 2013.
70. Chung YC, Lu LC, Tsai MH, et al: The inhibitory effect of ellagic acid on cell growth of ovarian carcinoma cells. Evid Based Complement Alternat Med 2013: 306705, 2013.
71. Li H, Sun L, Xu Y, et al: Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. PLoS One 8: e66679, 2013.
72. Chang MS, Kim DH, Roh JK, et al: Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-kappaB. J Virol 87: 10515-10523, 2013.
73. Jiang J, Huang X, Wang Y, Deng A and Zhou J: FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells. Mol Biol Rep 39: 8243-8250, 2012.
74. Li QY, Chi YY and Liu SQ: Cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models. Immunopharmacol Immunotoxicol 30: 365-381, 2008.
75. Gulappa T, Reddy RS, Suman S, Nyakeriga AM and Damodaran C: Molecular interplay between cdk4 and p21 dictates G/G cell cycle arrest in prostate cancer cells. Cancer Lett 337: 177-183, 2013.
76. Bermudez O, Hennen E, Koch I, Lindner M and Eickelberg O: Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation. PLoS One 8: e63226, 2013.
77. Aigelsreiter A, Ress AL, Bettermann K, et al: Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma. Br J Cancer 108: 1830-1837, 2013.
78. Guo J, Gao J, Li Z, et al: Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett 339: 185-194, 2013.
79. Yoon JS, Kim HM, Yadunandam AK, et al: Neferine isolated from Nelumbo nucifera enhances anti-cancer activities in Hep3B cells: Molecular mechanisms of cell cycle arrest, ER stress induced apoptosis and anti-angiogenic response. Phytomedicine 20: 1013-1022, 2013.
80. Kurokawa K, Akaike Y, Masuda K, et al: Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. Oncogene: March 18, 2013 (Epub ahead of print).
81. Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and Pang D: Fangchinoline induces G1 arrest in breast cancer cells through cell-cycle regulation. Phytother Res: Feb 11, 2013 (Epub ahead of print).
82. Steck PA, Pershouse MA, Jasser SA, et al : Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
83. Santoni M, Burattini L, Nabissi M, et al: Essential role of gli proteins in glioblastoma multiforme. Curr Protein Pept Sci 14: 133-140, 2013.
84. Yang P, Wang Y, Peng X, et al: Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol 113: 259-266, 2013.
85. Brucka A and Szyłło K: Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer. Ginekol Pol 84: 344-351, 2013.
86. Abdulkareem IH and Blair M: Effects of indomethacin on expression of PTEN tumour suppressor in human cancers. Niger Med J 54: 100-106, 2013.
87. McQuitty E, Zhang W, Hendrickson H, et al: Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. Arch Pathol Lab Med: Jun 26, 2013 (Epub ahead of print).
88. Filippini SE and Vega A: Breast cancer genes: beyond BRCA1 and BRCA2. Front Biosci 18: 1358-1372, 2013.
89. Alshaker H, Sauer L, Monteil D, et al: Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res 117: 143-200, 2013.
90. Lim KG, Tonelli F, Berdyshev E, et al: Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b. Int J Biochem Cell Biol 44: 1457-1464, 2012.
91. Rosa R, Marciano R, Malapelle U, et al: Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res 19: 138-147, 2013.
92. Lim KG, Tonelli F, Li Z, et al: FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 286: 18633-18640, 2011.
93. Tonelli F, Lim KG, Loveridge C, et al: FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 22: 1536-1542, 2010.
94. Pitson SM: Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 36: 97-107, 2011.
95. Li MH, Hla T and Ferrer F: Sphingolipid modulation of angiogenic factor expression in neuroblastoma. Cancer Prev Res (Phila) 4: 1325-1332, 2011.
96. Xu Z, Graham K, Foote M, et al: 14-3-3 targets chaperone-associated misfolded proteins to aggresomes. J Cell Sci 126: 4173-4186.
97. Zhang L, Chen J and Fu H: Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc Natl Acad Sci USA 96: 8511-8515, 1999.
98. Woodcock JM, Ma Y, Coolen C, et al: Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell Signal 22: 1291-1299, 2010.